The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab; AbbVie). The Food and Drug Administration (FDA) has approved Abrilada ...

The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...

On November 15, the FDA approved Pfizer’s Humira® biosimilar, ABRILADA (adalimumab-afzb). The acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® ...

In July 2020, the FDA authorised an Adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVie’s reference product Humira, which has been ...

(RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, ...

The FDA approved Nov. 18 Pfizer’s drug, Abrilada, a biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira. Abrilada’s approval brings the total number of FDA-approved biosimilars to 25.

The US Food and Drug Administration (FDA) has granted an interchangeability designation to adalimumab-afzb (Abrilada), according to an announcement from Pfizer. This is the second adalimumab ...

(RTTNews) - Pfizer Inc. (PFE) announced the FDA has approved ABRILADA as a biosimilar to Humira for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, ...